MedImmune maintained at neutral by Merrill

Merrill Lynch analyst Eric Ende kept MedImmune Inc. at its neutral rating. The announcement that Merck's Gardasil is recommended by the CDC boosts MedImmune's royalty revenue outlook. The Synagis guidelines could negatively affect the impact, however. Merrill lowered its 2006 earnings per share to $0.22 from $0.32, its 2007 estimate to $0.75 from $0.87, and the 2008 earnings-per-share estimates to $0.94 from $1.20. Shares of the Gaithersburg, Md.-based biotechnology company were down 2 cents, or 0.07%, at $27.10 on volume of 2,560,964 shares versus the three-month running average of 2,986,640 shares. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.